CORRECTING AND REPLACING/Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m (1) TP).
Pharmaceutical Technology on MSN

FDA increases manufacturing flexibility for cell and gene therapies

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.
The Caledonian-Record

Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, and AGC Biologics, your friendly CDMO expert, have signed a licensing agreement for Asimov’s off-the-shelf ...
TMCnet

Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine ...